We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
High-Dose Ascorbate in Combination with Anti-PD1 Checkpoint Inhibition as Treatment Option for Malignant Melanoma.
- Authors
Burkard, Markus; Niessner, Heike; Leischner, Christian; Piotrowsky, Alban; Renner, Olga; Marongiu, Luigi; Lauer, Ulrich M.; Busch, Christian; Sinnberg, Tobias; Venturelli, Sascha
- Abstract
Ascorbate acts as a prooxidant when administered parenterally at high supraphysiological doses, which results in the generation of hydrogen peroxide in dependence on oxygen. Most cancer cells are susceptible to the emerging reactive oxygen species (ROS). Accordingly, we evaluated high-dose ascorbate for the treatment of the B16F10 melanoma model. To investigate the effects of ascorbate on the B16F10 cell line in vitro, viability, cellular impedance, and ROS production were analyzed. In vivo, C57BL/6NCrl mice were subcutaneously injected into the right flank with B16F10 cells and tumor-bearing mice were treated intraperitoneally with ascorbate (3 g/kg bodyweight), immunotherapy (anti-programmed cell death protein 1 (PD1) antibody J43; 2 mg/kg bodyweight), or both treatments combined. The efficacy and toxicity were analyzed by measuring the respective tumor sizes and mouse weights accompanied by histological analysis of the protein levels of proliferating cell nuclear antigen (Pcna), glucose transporter 1 (Glut-1), and CD3. Treatment of B16F10 melanoma-carrying mice with high-dose ascorbate yielded plasma levels in the pharmacologically effective range, and ascorbate showed efficacy as a monotherapy and when combined with PD1 inhibition. Our data suggest the applicability of ascorbate as an additional therapeutic agent that can be safely combined with immunotherapy and has the potential to potentiate anti-PD1-based immune checkpoint blockades.
- Subjects
PROLIFERATING cell nuclear antigen; MELANOMA; IMMUNE checkpoint proteins; GLUCOSE transporters; REACTIVE oxygen species; PROGRAMMED cell death 1 receptors
- Publication
Cells (2073-4409), 2023, Vol 12, Issue 2, p254
- ISSN
2073-4409
- Publication type
Article
- DOI
10.3390/cells12020254